E S G P E R F O R M A N C E D A T A
ESG Performance Data 2021
We assess the effectiveness of our sustainability activities by monitoring key performance indicators (KPIs). The KPIs below give an indication of our performance in environment, social, and governance (ESG) topics over the past five years. For more information, please refer to our Non-FinancialGroup Report.
This index is currently only available in English.
2021 | 2020 | 2019 | 2018 | 2017 |
PATIENTS
Number of patients treated
Number of dialysis clinics worldwide
Number of dialysis treatments (millions)
Share of dialysis product market (%)
Share of dialysis patients treated worldwide (%)
North America (%)
Europe, Middle East and Africa (%)
Asia-Pacific (%)
Latin America (%)
345,425 ✓1 | 346,553 | ✓ | 345,096 | ✓ | 333,331 | ✓ | 320,960 | ✓ | |
4,171 | ✓ | 4,092 | ✓ | 3,994 | ✓ | 3,928 | ✓ | 3,752 | ✓ |
52.9 | ✓ | 53.6 | ✓ | 52.1 | ✓ | 50.0 | ✓ | 48.3 | ✓ |
36 | ✓ | 36 | ✓ | 36 | ✓ | 35 | ✓ | 35 | ✓ |
9 | ✓ | 9 | ✓ | 10 | ✓ | 10 | ✓ | 10 | ✓ |
30 | ✓ | 30 | ✓ | 31 | ✓ | 31 | ✓ | 31 | ✓ |
8 | ✓ | 8 | ✓ | 8 | ✓ | 8 | ✓ | 8 | ✓ |
2 | ✓ | 2 | ✓ | 2 | ✓ | 2 | ✓ | 2 | ✓ |
12 | ✓ | 12 | ✓ | 12 | ✓ | 11 | ✓ | 11 | ✓ |
- Figures marked with a ✓ are included in the Annual Report, which has been subject to a third-party assessment.
ESG Performance Data | Page 2 out of 12
2021 | 2020 | 2019 | 2018 | 2017 | |||||
QUALITY OF CARE AND PATIENT SATISFACTION | |||||||||
Number of key partnerships with academia, research | > 60 ✓ | > 40 ✓ | n/a2 | n/a | n/a | ||||
institutes, and peers | |||||||||
Net Promoter Score | 71 | ✓ | 67 | ✓ | n/a | n/a | n/a | ||
Patients who would highly recommend our services (%) | 78 | ✓ | 75 | ✓ | n/a | n/a | n/a | ||
Coverage rate of patient experience survey (%) | 91 | ✓ | 78 | ✓ | n/a | n/a | n/a | ||
Response rate of patient experience survey (%) | 75 | ✓ | 76 | ✓ | n/a | n/a | n/a | ||
Global hospitalization rate per patient in days | 10.7 | n/a | n/a | n/a | n/a | ||||
PRODUCT QUALITY AND SAFETY | |||||||||
Number of production sites worldwide | 42 | ✓ | 44 | ✓ | 45 | ✓ | 42 ✓ | 41 ✓ | |
Operations covered by quality management systems (%)3 | 98 | 98 | n/a | n/a | n/a | ||||
Number of product improvements to dialysis machines, | > 2,000 ✓ | > 440 ✓ | n/a | n/a | n/a | ||||
dialyzers, filters, and solution products4 | |||||||||
Audit score5 | 0.1 | ✓ | 0.2 | ✓ | 0.2 | ✓ | 0.3 | n/a | |
INNOVATION | |||||||||
R&D expenditures (thousand €) | 220,782 | ✓ | 193,774 | ✓ | 168,028 | ✓ | 114,074 ✓ | 110,997 ✓ | |
R&D expenditures as a percentage of health care product | 6 | ✓ | 5 | ✓ | 5 | ✓ | 3 ✓ | 3 | |
revenue (%) | |||||||||
Number of patents | 10,048 | ✓ | 11,223 | ✓ | 10,658 | ✓ | 9,152 ✓ | 8,396 ✓ | |
Number of patent families | 1,622 | ✓ | 1,626 | ✓ | 1,518 | ✓ | ~1,340 ✓ | 1,253 ✓ | |
- n/a = not available.
-
Includes ISO 9001/13485, Good Manufacturing Practice (GMP)/ Current Good Manufacturing Practice (cGMP), and Medical Device Single Audit Program (MDSAP).
4 In 2020, this figure only included the product improvements made to dialysis machines.
5 The audit score measures our performance in certification audits and indicates the ratio of major and critical findings to the number of external audits.
ESG Performance Data 2021 | Page 3 out of 12
2021 | 2020 | 2019 | 2018 | 2017 | |
Number of new patent families produced | 103 ✓ | 135 ✓ | 163 ✓ | 126 ✓ | 126 ✓ |
EMPLOYEES
Number of employees (headcount)
Number of employees (FTE)
EMPLOYEES PER REGION6
North America (%)
Latin America (%)
Europe, Middle East and Africa (incl. Germany) (%)
Germany (%)
Asia-Pacific (%)
Corporate (%)
EMPLOYEES PER FUNCTIONAL AREA6
Production and services (%)
Administration (%)
Sales and marketing (%)
Research and development (%)
INCLUSION AND DIVERSITY
Average age (years)
Employees under 30 years (%)
130,251 | ✓ | 133,129 | ✓ | 128,300 | ✓ | 120,328 | ✓ | 121,245 | ✓ |
122,909 | ✓ | 125,364 | ✓ | 120,659 | ✓ | 112,658 | ✓ | 114,000 | ✓ |
49 | ✓ | 50 | ✓ | 50 | ✓ | 50 | ✓ | 51 | ✓ |
10 | ✓ | 9 | ✓ | 9 | ✓ | 8 | ✓ | 8 | ✓ |
16 | ✓ | 17 | ✓ | 17 | ✓ | 17 | ✓ | 17 | ✓ |
6 | ✓ | 6 | ✓ | 6 | ✓ | 6 | ✓ | 5 | ✓ |
10 | ✓ | 10 | ✓ | 10 | ✓ | 10 | ✓ | 9 | ✓ |
15 | ✓ | 14 | ✓ | 14 | ✓ | 15 | ✓ | 15 | ✓ |
85 | ✓ | 86 | ✓ | 86 | ✓ | 86 | ✓ | 87 | ✓ |
10 | ✓ | 10 | ✓ | 10 | ✓ | 10 | ✓ | 9 | ✓ |
4 | ✓ | 3 | ✓ | 3 | ✓ | 3 | ✓ | 3 | ✓ |
1 | ✓ | 1 | ✓ | 1 | ✓ | 1 | ✓ | 1 | ✓ |
42 | ✓ | 42 | ✓ | 41 | ✓ | 41 | ✓ | 42 | ✓ |
16 | ✓ | 17 | ✓ | 18 | ✓ | 16 | ✓ | 18 | ✓ |
- Employees calculated as full-time equivalents (FTEs).
ESG Performance Data 2021 | Page 4 out of 12
2021 | 2020 | 2019 | 2018 | 2017 | ||
Employees between 30 and 50 years (%) | 58 ✓ | 58 ✓ | 56 ✓ | 57 ✓ | 56 | ✓ |
Employees over 50 years (%) | 26 ✓ | 25 ✓ | 26 ✓ | 27 ✓ | 26 | ✓ |
Female managers (%)7 | 59 | n/a | n/a | n/a | n/a | |
Female employees in entire company (%) | 69 ✓ | 69 ✓ | 69 ✓ | 69 ✓ | 69 | ✓ |
Female employees in North America (%) | 72 | 71 | 72 ✓ | 72 ✓ | 70 | ✓ |
Female employees in Europe, Middle East and Africa (%) | 67 | 66 | 66 ✓ | 67 ✓ | 67 | ✓ |
Female employees in Latin America (%) | 67 | 66 | 65 ✓ | 67 ✓ | 68 | ✓ |
Female employees in Asia-Pacific (%) | 65 | 65 | 64 ✓ | 65 ✓ | 65 | ✓ |
Management Board members between 30 and 50 years (%) | 12.5 | 12.5 | 14.3 | 14.3 | 28.6 | |
Management Board members over 50 years (%) | 87.5 | 87.5 | 85.7 | 85.7 | 71.4 | |
Share of women in the Management Board (%) | 25 ✓ | 25 ✓ | 29 ✓ | 14 ✓ | 0 | ✓ |
Supervisory Board members between 30 and 50 years (%) | 0 | 0 | 16.7 | 0 | 16.7 | |
Supervisory Board members over 50 years (%) | 100 | 100 | 83.3 | 100 | 83.3 | |
Share of women in the Supervisory Board (%) | 33 ✓ | 33 ✓ | 33 ✓ | 33 ✓ | 33 | ✓ |
Women at first management level (%)8 | 18 ✓ | 18 ✓ | 23 ✓ | 21 ✓ | 19 | ✓ |
Women at second management level (%)9 | 28 ✓ | 28 ✓ | 30 ✓ | 27 ✓ | 28 | ✓ |
Female Long-Term Incentive Plan (LTIP) participants (%) | 34 ✓ | 34 ✓ | 34 ✓ | 33 ✓ | 33 | ✓ |
Non-Germans within the Management Board (%) | 75 | 75 | 71 | 71 | 86 | |
- Managers are defined as employees with direct reports. The figure is as of March 31, 2021.
-
Figures from 2017 to 2019 include all employees that participate in our Long-Term Incentive Plan (LTIP) and report directly to a Management Board member. For 2020 and 2021, figures include all managers in respective leadership positions according to our new global job evaluation system.
9 Figures from 2017 to 2019 include all employees that participate in our Long-Term Incentive Plan (LTIP) and report directly to a first-level leader. For 2020 and 2021, figures include all managers in respective leadership positions according to our new global job evaluation system.
ESG Performance Data 2021 | Page 5 out of 12
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
FMC - Fresenius Medical Care AG & Co. KGaA published this content on 31 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2022 16:00:01 UTC.